Skip to content
LATEST
Markets

OrbiMed Advisors buys $20m stake in Windward Bio

The healthcare investment firm expanded its direct holding by 221% through a share purchase disclosed in a regulatory filing.

OrbiMed Advisors buys $20m stake in Windward Bio

OrbiMed Advisors LLC purchased 1,176,471 shares of Windward Bio Group AG for $20,000,007 on Nov. 16, according to an ownership disclosure filed with the U.S. Securities and Exchange Commission.

The transaction expanded the investment firm's direct position in the clinical-stage biotechnology company by 221.29% to 1,708,103 shares. At completion, the total holding carried a valuation of $29,037,751, the filing showed.

OrbiMed, which holds a board seat at the drug developer, acquired the stock at an average price of $17.00 per share. Windward Bio opened at $24.28 in Friday trading on the Nasdaq, within a 52-week band of $18.35 to $33.99.

Windward Bio develops ultra-long-acting antibody therapies directed at chronic respiratory and dermatological disorders, including asthma, chronic obstructive pulmonary disease, and atopic dermatitis. The company's lead drug candidate is WIN378, an anti-TSLP monoclonal antibody, alongside WIN027, a clinical-stage bi-specific antibody targeting both TSLP and IL-13 pathways.

Source: Securities filing, U.S. Securities and Exchange Commission, Nov. 21, 2026.

More stories

Latest news